● Single award · contract
Barda Will Implement a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Trial in the US to…
A single federal award, with both ends of the trail linked.
$117.4M
total award value
2023
action date
81 mo
period
75A50124C00001
PIID
Description
Barda Will Implement a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Trial in the US to Evaluate the Safety and Efficacy of Novel Host-Directed Therapeutic Candidates in Hospitalized Adults with Ards.
Awarding agencyDepartment of Health and Human Services →
RecipientOutside our Phase 1 contractor set: see methodology
Place of performanceNorth Carolina →
CategoryNAICS 541714PSC AN12
Competed?Not recorded✓ from source
Total (exact)$117,399,278
More from Department of Health and Human Services
awarded 2024$100.1B
awarded 2023$92B
awarded 2022$80.5B
awarded 2021$80.5B
awarded 2022$71.7B
🔎
Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are ✓ from source; anything we compute or infer (corporate parents, districts, competitors) is ≈ inferred and worded carefully, never asserted as fact.